Evaluation and Management of Psoriasis: An Internist's Guide

Medical Clinics of North America

Volumn 93, Issue 6, 2009, Pages 1291-1303

  Levine, Danielle ^a   Gottlieb, Alice ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biologics; Immunopathogenesis; Metabolic syndrome; Plaque; Psoriasis

Indexed keywords

ADALIMUMAB; ALEFACEPT; CALCIPOTRIOL; CORTICOSTEROID; CYCLOSPORIN A; DITHRANOL; EFALIZUMAB; ETANERCEPT; ETRETIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; PIMECROLIMUS; PLACEBO; RETINOL; TACALCITOL; TACROLIMUS; TAR; TAZAROTENE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VITAMIN D;

ABORTION; BONE MARROW SUPPRESSION; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DRUG WITHDRAWAL; GINGIVA HYPERTROPHY; HEADACHE; HEREDITY; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFECTION; LIVER TOXICITY; MONOTHERAPY; NEPHROTOXICITY; PATHOGENESIS; PHOTOTHERAPY; PHYSICAL EXAMINATION; PNEUMONIA; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SKIN CANCER; TERATOGENICITY; TREMOR;

COMORBIDITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHOTOTHERAPY; PSORIASIS; RISK FACTORS;

EID: 70449673116     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2009.08.003     Document Type: Review

References (51)

1. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 3 (2004) 121
2. Gottlieb A.B., Dann F., and Menter A. Psoriasis and the metabolic syndrome. J Drugs Dermatol 7 6 (2008) 563-572
3. Gelfand J.M., Stern R.S., Nijsten T., et al. The prevalence of psoriasis in African-Americans: results from a population-based study. J Am Acad Dermatol 52 (2005) 23
4. Gudjonsson J.E., and Elder J.T. Psoriasis. In: Wolff K., Goldsmith L.A., Katz S.L., et al. (Eds). Fitzpatrick's dermatology in general medicine. 7th edition (2008), McGraw-Hill, New York 170-193
5. Elder J.T., Nair R.P., Guo S.W., et al. The genetics of psoriasis. Arch Dermatol 130 (1994) 216
6. Tomfohrde J., Silverman A., Barnes R., et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 264 (1994) 1141
7. Sagoo G.S., Cork M.J., Patel R., et al. Genome-wide studies of psoriasis susceptibility loci: a review. J Dermatol Sci 35 (2004) 171
8. Huerta C., Rivero E., and Rodríguez L.A. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 143 (2007) 1559
9. Setty A.R., Curhan G., and Choi H.K. Smoking and the risk of psoriasis in women: Nurses' Health Study II. Am J Med 120 (2007) 953
10. Sterry W., Strober B.E., and Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications, report of an interdisciplinary conference and review. Br J Dermatol 157 (2007) 649-655
11. Wenzel F.G., and Morison W.L. Psoriasis. In: Stein J.H., Sande M.A., Zvaifler N.A., et al. (Eds). Internal medicine. 5th edition (1998), Mosby, St Louis (MO) 2041-2050
12. Gottlieb A.B. Psoriasis. Dis Manag Clin Outcomes 1 (1998) 195-202
13. Boyd A.S., and Menter A. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol 21 (1989) 985
14. Ragaz A., and Ackerman A.B. Evolution, maturation, and regression of lesions of psoriasis. New observations and correlation of clinical and histologic findings. Am J Dermatopathol 1 3 (1979) 199-214
15. Lowes M.A., Bowcock A.M., and Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 445 7130 (2007) 866-873
16. Gottlieb A.B. Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov 4 1 (2005) 19-34
17. Zhou X., Krueger J.G., Kao M.C., et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 13 (2003) 69-78
18. Bettelli E., Carrier Y., Gao W., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441 (2006) 235-238
19. Lee E., Trepicchio W.L., Oestreicher J.L., et al. Increased expression if interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199 (2004) 125-130
20. Wilson N.J., Boniface K., Chan J.R., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8 9 (2007) 950-957
21. Asarch A., Barak O., Loo D.S., et al. Th17 cells: a new paradigm for cutaneous inflammation. J Dermatolog Treat 19 5 (2008) 259-266
22. Chan J.R., Blumenschein W., Murphy E., et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 203 (2006) 2577-2587
23. Krueger G.G., Langley R.G., Leonardi C., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356 (2007) 580-592
24. Gelfand J.M., Troxel A.B., Lewis J.D., et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 143 (2007) 1493-1499
25. Gottlieb A., Korman N.J., Gordon K.B., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 58 5 (2008) 851-864
26. Najarian D.J., and Gottlieb A.B. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol 48 (2003) 805-821
27. Broadley S.A., Deans J., Sawcer S.J., et al. Autoimmune disease in first-degree relatives of patients with multiple sclerosis: a UK survey. Brain 123 (2000) 1102-1111
28. Gisondi P., Tessari G., Conti A., et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 157 (2007) 68-73
29. Gelfand J.M., Neimann A.L., Shin D.B., et al. Risk of myocardial infarction in patients with psoriasis. JAMA 296 (2006) 1735-1741
30. Menter A., Gottlieb A., Feldman S.R., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58 5 (2008) 826-850
31. Gelfand J.M., Berlin J., Van Voorhees A., et al. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 139 (2003) 1425-1429
32. Tyring S., Gottlieb A., Papp K., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet 367 (2006) 29-35
33. Rapp S.R., Feldman S.R., Exum M.L., et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41 (1999) 401-407
34. Stern R.S., Nijsten T., Feldman S.R., et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 9 (2004) 136-139
35. Feldman SR, Pearce DJ. Treatment of psoriasis. In: Dellavalle section editor. UpToDate, version 16.2. May 2008. Available at: www.uptodate.com. Accessed October 23, 2008.
36. Koo J., Blum R.R., and Lebwohl M. A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. J Am Acad Dermatol 55 (2006) 637
37. Kaufmann R., Bibby A.J., Bissonnette R., et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 205 (2002) 389
38. Stern R.S. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 44 (2001) 755
39. Roenigk Jr. H.H., Auerbach R., Maibach H.I., et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 19 (1988) 145-156
40. Ellis C.N., Fradin M.S., Messana M.D., et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 324 (1991) 277-284
41. Lebwohl M., Drake L., Menter A., et al. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol 45 (2001) 544
42. Krueger J.G. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46 (2002) 1-23
43. Berger E.M., and Gottlieb A.B. Developments in systemic immunomodulatory therapy for psoriasis. Curr Opin Pharmacol 7 4 (2007) 434-444
44. Lebwohl M., Bagel J., Gelfand J.M., et al. From the medical board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 58 (2008) 94-105
45. Krueger G.G., Gottlieb A.B., Sterry W., et al. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis. J Dermatolog Treat 19 3 (2008) 146-155
46. Alafecept. [package insert]. Available at. http://www.fda.gov/cder/foi/label/2003/alefbio013003LB.htm Accessed November 22, 2008
47. Lebwohl M., Tyring S.K., Hamilton T.K., et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349 21 (2003) 2004-2013
48. Menter A., Tyring S.K., Gordon K., et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 58 (2007) 106-115
49. Leonardi C.L., Powers J.L., Matheson R.T., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349 (2003) 2014-2022
50. Reich K., Nestle F.O., and Papp K. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005) 1367-1374
51. Gottlieb A.B., Evans R., Li S., et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, doubleblind, placebo-controlled trial. J Am Acad Dermatol 51 (2004) 534-542